Answers are grounded in this paper and cite their sources.
Objective This study aims to assess the clinical efficacy of arthroscopic knee debridement combined with platelet-rich plasma (PRP) for knee osteoarthritis (KOA). Materials and methods This study was designed as a prospective randomized controlled trial. A total of 120 patients diagnosed with knee osteoarthritis (KOA) and scheduled for arthroscopic knee debridement were enrolled at our hospital between June 2023 and December 2024. We randomly assigned 120 patients into two groups: the HAS group (sodium hyaluronate) and the PRP group (platelet-rich plasma), with 60 patients in each group. Group A (sodium hyaluronate, HAS group) and Group B (platelet-rich plasma, PRP group), with 60 patients in each group. Clinical efficacy was evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), and knee flexion range of motion (ROM) at baseline and at 4, 12, 24, and 48 weeks post-treatment. Adverse events and complications were also recorded. In addition, MRI-based MOCART scores were assessed at baseline and 48 weeks post-treatment. Results At 4, 12, 24, and 48 weeks postoperatively, the knee range of motion (ROM), VAS score, and WOMAC score in both groups were significantly improved compared with those before surgery, with statistically significant differences ( P < 0.05). At 4 weeks postoperatively, the VAS and WOMAC scores of the HAS group were superior to those of the PRP group ( P < 0.05), while there was no statistically significant difference in knee ROM between the two groups ( P > 0.05). At 12 weeks postoperatively, the knee ROM of the PRP group was better than that of the HAS group ( P < 0.05), but there was no statistically significant difference in VAS and WOMAC scores between the two groups ( P > 0.05). At 24 and 48 weeks postoperatively, the knee ROM, VAS score, and WOMAC score of the PRP group were significantly superior to those of the HAS group, with highly statistically significant differences ( P < 0.001). At 48 weeks after treatment, the MOCART score of the PRP group showed a significant improvement compared to the HAS group ( P < 0.05). There was no statistically significant difference in the incidence of complications between the two groups ( P > 0.05). Conclusion Both arthroscopic knee debridement combined with PRP and that combined with HAS can effectively improve knee range of motion (ROM), alleviate pain, and recover knee function. Specifically, among patients undergoing arthroscopic knee debridement, the combination with HAS yielded superior outcomes at 4 weeks postoperatively, whereas the combination with PRP achieved significantly better outcomes from 12 to 48 weeks after surgery, and PRP was associated with superior MOCART scores on MRI at 48 weeks. However, the between-group differences in pain were modest (0.5–1 point on the VAS) and below the minimal clinically important difference; therefore, these findings should be interpreted with caution. Clinical Trial Registration identifier ChiCTR2300070418.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: